Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1

  • Authors:
    • Andreea M. Bujor
    • Paul Haines
    • Cristina Padilla
    • Romy B. Christmann
    • Monica Junie
    • Percival D. Sampaio-Barros
    • Robert Lafyatis
    • Maria Trojanowska
  • View Affiliations

  • Published online on: October 5, 2012     https://doi.org/10.3892/ijmm.2012.1150
  • Pages: 1473-1480
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Systemic sclerosis (SSc) is characterized by fibrosis of the skin and internal organs. The present study was undertaken to examine the effects of ciprofloxacin, a fluoroquinolone antibiotic implicated in matrix remodeling, on dermal and lung fibroblasts obtained from SSc patients. Dermal and lung fibroblasts from SSc patients and healthy subjects were treated with ciprofloxacin. Western blotting was used to analyze protein levels and RT-PCR was used to measure mRNA expression. The pharmacologic inhibitor UO126 was used to block Erk1/2 signaling. SSc dermal fibroblasts demonstrated a significant decrease in collagen type I mRNA and protein levels after antibiotic treatment, while healthy dermal fibroblasts were less sensitive to ciprofloxacin, downregulating collagen only at the protein levels. Connective tissue growth factor (CCN2) gene expression was significantly reduced and matrix metalloproteinase 1 (MMP1) levels were enhanced after ciprofloxacin treatment to a similar extent in healthy and SSc fibroblasts. Ciprofloxacin induced Erk1/2 phosphorylation, and Erk1/2 blockade completely prevented MMP1 upregulation. However, Smad1 and Smad3 activation in response to TGFβ was not affected. The expression of friend leukemia integration factor 1 (Fli1), a transcriptional repressor of collagen, was increased after treatment with ciprofloxacin only in SSc fibroblasts, and this was accompanied by a decrease in the levels of DNA methyltransferase 1 (Dnmt1). Similar effects were observed in SSc-interstitial lung disease (ILD) lung fibroblasts. In summary, our study demonstrates that ciprofloxacin has antifibrotic actions in SSc dermal and lung fibroblasts via the downregulation of Dnmt1, the upregulation of Fli1 and induction of MMP1 gene expression via an Erk1/2-dependent mechanism. Thus, our data suggest that ciprofloxacin may be an attractive therapy for SSc skin and lung fibrosis.
View Figures
View References

Related Articles

Journal Cover

December 2012
Volume 30 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bujor AM, Haines P, Padilla C, Christmann RB, Junie M, Sampaio-Barros PD, Lafyatis R and Trojanowska M: Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1. Int J Mol Med 30: 1473-1480, 2012
APA
Bujor, A.M., Haines, P., Padilla, C., Christmann, R.B., Junie, M., Sampaio-Barros, P.D. ... Trojanowska, M. (2012). Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1. International Journal of Molecular Medicine, 30, 1473-1480. https://doi.org/10.3892/ijmm.2012.1150
MLA
Bujor, A. M., Haines, P., Padilla, C., Christmann, R. B., Junie, M., Sampaio-Barros, P. D., Lafyatis, R., Trojanowska, M."Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1". International Journal of Molecular Medicine 30.6 (2012): 1473-1480.
Chicago
Bujor, A. M., Haines, P., Padilla, C., Christmann, R. B., Junie, M., Sampaio-Barros, P. D., Lafyatis, R., Trojanowska, M."Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1". International Journal of Molecular Medicine 30, no. 6 (2012): 1473-1480. https://doi.org/10.3892/ijmm.2012.1150